News & Updates

In patients with previously untreated CD20+ diffuse large B-cell lymphoma (DLBCL), treatment with subcutaneous (SC) rituximab is not inferior to intravenous (IV) rituximab in terms of serum trough levels, efficacy, and tolerability, as shown in a study presented at EHA 2023.

Obesity does not seem to have any significant impact on clinical outcomes, particularly survival, in patients with multiple myeloma (MM), according to a study presented at EHA 2023. However, obese MM patients aged <65 years tend to have a shorter overall survival (OS) than those with normal weight.

Certain comorbidities such as hypertension and diabetes mellitus (DM), along with locally advanced stage at diagnosis and systemic treatment received (ie, doxorubicin), are significantly associated with tumour recurrences among patients with breast cancer, according to a study presented at the recent ASCO Breakthrough 2023.

A trend towards a favourable overall (OS) and disease-free survival (DFS) at 21 months follow-up has been observed among patients with early breast cancer enrolled to a government program that grants medicines access to indigent individuals, reports a study presented at ASCO Breakthrough 2023.

Patients with chronic myeloid leukaemia (CML) who are being treated with both tyrosine kinase inhibitors (TKIs) and selective serotonin reuptake inhibitors (SSRIs) do not appear to be at greater total risk of bleeding or thrombotic events than those on TKIs only, reveals a study. However, concomitant use of TKIs and SSRIs may elevate the risk of intracranial bleeding.

Using hydrochlorothiazide (HCTZ) for longer durations and in higher cumulative doses increases the risks for keratinocyte carcinoma and melanoma, reveals a study.